OptimizeRx (NASDAQ:OPRX) Given Market Outperform Rating at JMP Securities

JMP Securities reissued their market outperform rating on shares of OptimizeRx (NASDAQ:OPRX) in a research report released on Tuesday, Benzinga reports. JMP Securities currently has a $15.00 target price on the stock.

Several other brokerages have also commented on OPRX. Stifel Nicolaus restated a buy rating and set a $13.00 target price on shares of OptimizeRx in a research report on Monday, April 1st. Royal Bank of Canada restated an outperform rating and set a $17.00 target price on shares of OptimizeRx in a research report on Monday, April 1st. Finally, Barclays started coverage on shares of OptimizeRx in a research report on Wednesday, January 3rd. They set an equal weight rating and a $15.00 target price on the stock. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, OptimizeRx presently has a consensus rating of Moderate Buy and an average target price of $15.86.

OptimizeRx Trading Down 1.9 %

NASDAQ:OPRX opened at $9.35 on Tuesday. The firm’s fifty day moving average price is $13.36 and its 200 day moving average price is $11.95. OptimizeRx has a 1-year low of $6.92 and a 1-year high of $16.65.

Institutional Investors Weigh In On OptimizeRx

Several institutional investors and hedge funds have recently made changes to their positions in the business. Thrivent Financial for Lutherans boosted its position in shares of OptimizeRx by 4.5% in the 3rd quarter. Thrivent Financial for Lutherans now owns 18,631 shares of the company’s stock worth $276,000 after buying an additional 797 shares in the last quarter. Nuveen Asset Management LLC boosted its position in shares of OptimizeRx by 1.7% in the 3rd quarter. Nuveen Asset Management LLC now owns 49,959 shares of the company’s stock worth $741,000 after buying an additional 842 shares in the last quarter. Captrust Financial Advisors boosted its position in shares of OptimizeRx by 248.8% in the 2nd quarter. Captrust Financial Advisors now owns 1,287 shares of the company’s stock worth $35,000 after buying an additional 918 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of OptimizeRx by 2.3% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 45,103 shares of the company’s stock worth $1,701,000 after buying an additional 1,033 shares in the last quarter. Finally, Point72 Hong Kong Ltd boosted its position in shares of OptimizeRx by 81.6% in the 2nd quarter. Point72 Hong Kong Ltd now owns 2,492 shares of the company’s stock worth $68,000 after buying an additional 1,120 shares in the last quarter. 76.47% of the stock is currently owned by hedge funds and other institutional investors.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow.